Lexicon Pharmaceuticals Reports Third-Quarter Revenue of $11.25M, EPS Loss of $0.03
Revenue declined year over year and the net loss widened. Lower Novo Nordisk licensing and milestone revenue and higher selling, general and administrative expense more than offset reduced research and development and interest expense.
Third-quarter revenue declined year over year, while the net loss widened. Lower Novo Nordisk licensing and milestone revenue and increased selling, general and administrative expense more than offset reduced research and development and interest expense.Financial Highlights¹ Reported as “Total rev…